Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: a retrospective immunohistochemical study

Abstract

AimTo immunohistochemically evaluate the expression of MAGE-A1, MAGE-A, and NY-ESO-1 cancer/testis (C/T) tumor antigens in medullary breast cancer (MBC) tumor samples and to analyze it in relation to the clinicopathological features.MethodsThis retrospective study included samples from 49 patients: 40 with typical MBC and 9 with atypical MBC. Tumor specimens were obtained from patients operated on in the University Hospital for Tumors and the Sisters of Mercy University Hospital, Zagreb, Croatia, from 1999 to 2005. Standard immunohistochemistry was used on archival paraffin-embedded MBC tissues.ResultsMAGE-A1, MAGE-A, and NY-ESO-1 antigens were expressed in 33% (16/49), 33% (16/49), and 22% (11/49) of patients, respectively. No difference between the groups with and without C/T tumor antigen expression in age at diagnosis, tumor size, axillary lymph node metastasis, adjuvant therapy, and HER-2 expression was identified. Significantly more patients died in the MAGE-A-positive group than in the MAGE-A-negative group (P = 0.010), whereas a borderline significance was found between MAGE-A1-positive and the MAGE-A1-negative group (P = 0.079) and between NY-ESO-1-positive and NY-ESO-1-negative group (P = 0.117). Overall survival, as evaluated by the Kaplan-Meier curves, was lower in MAGE-A1- (P = 0.031), MAGE-A- (P = 0.004), NY-ESO-1-positive groups (P = 0.077).ConclusionExpression of C/T antigens may represent a marker of potential prognostic relevance in MBC.

Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis

“…Ademuyiwa et al [1] reported that NY-ESO-1 expression was associated with better progression-free survival in TNBC, though it was not statistically significant. On the contrary, Matkovic et al [40] reported that NY-ESO-1 expression was associated with poor overall survival in medullary breast cancer; however, the study population was relatively small (49 patients) and included HR-positive patients. Both studies did not analyze the prognostic value of NY-ESO-1 expression according to the adjuvant chemotherapy status.…”

Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen‐A family and NY‐ESO‐1 cancer‐testis antigens represents an independent marker for poor survival in head and neck cancer

“…CTAs have already been analyzed in different types of malignancies, including carcinomas of the liver, pancreas, bladder and the breast . CTA expression in lung cancer, medullary breast and urothelial carcinoma has also been found to impact patients' OS …”

“…[29][30][31][32] CTA expression in lung cancer, medullary breast and urothelial carcinoma has also been found to impact patients' OS. [33][34][35] In HNSCC, only two studies have analyzed protein expression of CTA, both with limited patient numbers and only one primary site included. 18,19 The second study was performed by Campos Montoro et al 19 and analyzed 23 oral squamous cell carcinomas.…”

A Novel Cancer Testis Antigen, A-Kinase Anchor Protein 4 (AKAP4) Is a Potential Biomarker for Breast Cancer

“…Comparing with other CT antigens, MAGE-C1/CT7 expression was found only in 18% (22 of 124) of invasive breast cancer patients [31]. Recently, MAGE-A1, MAGE-A, and NY-ESO-1 protein expression was reported only in 33% (16/49), 33% (16/49), and 22% (11/49) of breast cancer patients, respectively by IHC analysis [32]. In addition, the three other CT antigens –GAGE, SAGE1 and Nuclear RNA export factor 2 (NXF2), were infrequently or rarely expressed, only in 3.5%, 2.2% and 1.8% of the breast cancer patients, respectively [33].…”